As of November 15, 2026, enGene Therapeutics Inc. is a publicly traded company (Nasdaq: ENGN); its largest reported holder is Perceptive Advisors, with 9.99% on Schedule 13G/A of August 14, 2026, then BML Investment Partners, L.P. (9.95%). The largest insider holding is Forbion Growth Management B.V., a 10% owner, with 6,798,362 shares (10.1% of shares outstanding), per Form 4 of November 1, 2024 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in enGene Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is enGene Therapeutics Inc. a real, registered company?
- enGene Therapeutics Inc files with the SEC under CIK 1980845 (its SEC filings).
- Its shares are listed under the ticker ENGN on Nasdaq (also ENGNW) (SEC company record).
- Incorporated in Z4, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under enGene Therapeutics Inc in our court records and SEC 8-K records (as of 2026-11-15).
- Layoffs: 2 exit or restructuring plans reported on Form 8-K, Item 2.05 (latest filed 2026-06-18).
- Leadership changes: the latest reported is Richard Glickman, Director (Form 8-K filed 2026-07-16). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Eventide Asset Management, LLC (filed 2026-11-13).
Who are enGene Therapeutics Inc.'s owners and officers?
enGene Therapeutics Inc.: industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-13 | Eventide Asset Management, LLC | 5.1% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 0% |
| Schedule 13G/A, 2026-08-14 | Venrock Healthcare Capital Partners Iii, L.P. | 0% |
| Schedule 13G/A, 2026-08-13 | Raymond Debbane | 9.3% |
| Schedule 13G/A, 2026-08-12 | Blue Owl Capital Holdings LP | 0.76% |
| Schedule 13G, 2026-07-22 | Anders Hove | 5% |
| Schedule 13G/A, 2026-05-15 | Cormorant Asset Management, LP | 0% |
| Schedule 13G/A, 2026-05-14 | Bml Investment Partners, L.P. | 9.95% |
| Schedule 13G, 2026-05-13 | Bml Investment Partners, L.P. | 7.8% |
| Schedule 13G/A, 2026-05-05 | Raymond Debbane | 7.8% |
| Schedule 13G, 2026-02-17 | Cormorant Asset Management, LP | 5.97% |
Questions about who owns enGene Therapeutics Inc.
Who owns enGene Therapeutics Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of enGene Therapeutics Inc.: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Bml Investment Partners, L.P. (9.95%, Schedule 13G/A, filed 2026-05-14), Raymond Debbane (9.3%, Schedule 13G/A, filed 2026-08-13), Eventide Asset Management, LLC (5.1%, Schedule 13G, filed 2026-11-13) and Anders Hove (5%, Schedule 13G, filed 2026-07-22).
Who are the largest shareholders of enGene Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of enGene Therapeutics Inc. on this page are Perceptive Advisors LLC (9.99%), Bml Investment Partners, L.P. (9.95%) and Raymond Debbane (9.3%).
When did Perceptive Advisors LLC buy into enGene Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on enGene Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on enGene Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on enGene Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-16 | Richard Glickman | Director | departed | |
| Form 8-K, 2026-06-15 | Hussein Sweiti | Chief Medical Officer | departed | 2026-06-14 |
Which insiders own enGene Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Forbion Growth Management B.V., a 10% owner: 6,798,362 shares (10.1% of shares outstanding), 3,032,430 held directly and 3,765,932 indirectly, on a joint filing (Form 4, 2024-11-01).
- Forbion Growth Opportunities Fund I Cooperatief U.A., a 10% owner: 6,798,362 shares (10.1% of shares outstanding), 3,032,430 held directly and 3,765,932 indirectly, on a joint filing (Form 4, 2024-11-01).
- , a director: 20,000 shares (0.03% of shares outstanding) (Form 3, 2025-07-08).
- , the chief executive and a director: 10,000 shares (0.01% of shares outstanding) (Form 4, 2024-10-01).
- , the chief regulatory officer: 7,500 shares (0.01% of shares outstanding) (Form 3, 2025-07-14).
Shares outstanding: 67,016,316 as of 2026-09-02, from the company's latest SEC cover page.
How much has enGene Therapeutics Inc. raised?
No fundraising or offering filing from enGene Therapeutics Inc. is on file with us.
Red flags found
2 exit or restructuring plans on Form 8-K (latest Form 8-K, 2026-06-18).
Keep reading
More on enGene Therapeutics Inc. and the records around it.
enGene Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Jul 2026
- Layoff notices Jun 2026
Companies that share a holder
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), Athira Pharma, Inc. (Aug 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 11 other companies: ImageneBio, Inc. (Nov 2026), Latigo Biotherapeutics, Inc. (Nov 2026), Context Therapeutics Inc. (Aug 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/engene-therapeutics